microbiome
-
Skin Microbiome and Allergies: Understanding the Role of Microbes in Allergic Skin Conditions
Future research should focus on identifying the interactions between the immune system, microbes, and allergic responses; and exploring potential therapeutic strategies targeting the skin microbiome for allergy management.
-
Seres’s Bacteria in a Pill Becomes First FDA-Approved Oral Microbiome Therapy
Recurrent Clostridioides difficile infection can be treated with fecal microbiota transplants. FDA approval of Seres Therapeutics’ Vowst makes it the first oral microbiome therapy.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
MedCity Influencers, BioPharma
Industrial Scale Microbiome Mining is a New Drug Discovery Toolbox
Within ten years of execution and widespread adoption, most pipelines will be traced to the opportunity of untapped microbes of the earth.
-
Novome gets $43.5M boost for its engineered microbiome therapies
Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds. The biotech will use the money to advance clinical testing for its lead drug candidate, which seeks to decrease patients’ urinary oxalate, as well as advance its pipeline of preclinical genetically engineered microbes.
-
Takeda ends microbiome alliance with Finch Therapeutics after pipeline review
The agreement termination means that two preclinical microbiome therapy candidates for inflammatory bowel disease will now return to Finch Therapeutics. The biotech company had been collaborating with Takeda Pharmaceutical since 2017.
-
Persephone rakes in $15M to support country’s biggest cancer microbiome study
Persephone Biosciences, a preclinical biotech focused on microbiome-based medicines, raised $15 million in seed funding on Tuesday. The company will use the money to advance its trial for oncology therapeutics, as well as to continue developing its preventive medicine for infants.
-
Microbiome biotech Kaleido Biosciences shutters amid cash crunch, drug setbacks
Kaleido Biosciences, formed by Flagship Pioneering as part of a wave of biotech companies developing microbiome therapies, has laid off its entire workforce and is winding down operations. The shutdown follows a strategic review that failed to turn up any deals to support its clinical-stage pipeline.
-
Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm
Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.
-
Vedanta Bio guts out microbiome trial win to keep up with field, get BARDA cash
Vedanta Biosciences is developing its microbiome therapy with support from the Biomedical Advanced Research and Development Authority. Under terms of that contract, the positive Phase 2 results in preventing recurrent C. diff infection trigger a $23.8 million payment.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
FDA warns Kaleido Bio to test its Covid-19 candidate as a drug, not a medical food
The FDA issued a warning letter to Kaleido Biosciences alleging the company tested its experimental microbiome product in Covid-19 patients without submitting a formal clinical trial application. Kaleido claims the filing was not required because the product is a medical food, but the regulator doesn’t buy that argument.
-
The precipitous decline of once-promising microbiome startup uBiome
Here’s how the San Francisco company went from being an investor darling valued at $600 million to being under investigation by the FBI for its corporate practices.
-
uBiome appoints general counsel as interim CEO; founders placed on leave
The appointment of John Rakow follows a raid on the company’s offices in San Francisco last week connected with an investigation into allegations it had been double billing insurers.
-
Vedanta Biosciences raises $27M in Series C round
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
-
uBiome closes $83M Series C financing round to advance microbiome programs
The company also appointed to its board former Novartis CEO Joe Jimenez, who was involved with the Swiss drugmaker’s hiring of former Trump attorney Michael Cohen.